MRM-3379 enters patient testing for Fragile X syndrome in Mirum’s BLOOM Phase 2 trial
MRM-3379 enters Phase 2 testing for Fragile X syndrome. Find out what this means for PDE4D inhibition, IDD drug design, and future trial direction.
Pharma & Biotech